Thus, target treatment on RIPK2 showed an ideal control of inflammatory diseases, such as cystic fibrosis, asthma, inflammatory bowel disease and pancreatitis [3, 25, 26]. The gene discussed is RIPK2; the disease is cystic fibrosis.